Can a lupus drug protect kidneys in IgA disease? new trial aims to find out.

NCT ID NCT06350630

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether hydroxychloroquine, a drug already used for lupus, can slow kidney function decline in people with IgA nephropathy (Berger's disease). About 334 adults with biopsy-confirmed IgA nephropathy and high protein in their urine will receive either hydroxychloroquine or a placebo for up to 2 years. The goal is to see if the drug helps preserve kidney function and reduce protein leakage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY

Contacts and locations

Locations

AP-HM Hôpital de la Conception
RECRUITING

Marseille, 13385, France
APHP Hôpital Bichat
RECRUITING

Paris, 75018, France
APHP Hôpital de Tenon
RECRUITING

Paris, 75020, France
CHU Gabriel Montpied
RECRUITING

Clermont-Ferrand, 63000, France
CHU Lyon Sud
RECRUITING

Pierre-Bénite, 69495, France
CHU de Saint-Etienne
RECRUITING

Saint-Etienne, 42055, France
Hospices Civils de Lyon
RECRUITING

Lyon, 69437, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.